Skip to content

MAXimizing Flow Diversion Effect On the Treatment of Large Intracranial Aneurysms With Embolization Devices

MAX-PIPE Registry - Maximizing Flow Diversion Effect On The Treatment of Large Intracranial Aneurysms With PIPEline Flex Embolization Devices Using Optical Flow Imaging Software AneurysmFlow

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03161769
Acronym
MAX-PIPE
Enrollment
30
Registered
2017-05-22
Start date
2017-04-21
Completion date
2019-09-01
Last updated
2018-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysm

Brief summary

Investigate the ability of the intra-operative, intra-aneurysmal flow evaluation to assist with the treatment of intracranial large aneurysms using Embolization Device(s)

Detailed description

The Division of Neuroradiology at UHN (Toronto Western Hospital) would like to initiate a single center registry study on the treatment of large intracranial aneurysms with PIPEline\[tm\] flex embolization devices using optical flow imaging software, AneurysmFlow. The study team will consent patients diagnosed with unruptured brain / intracratial aneurysms IA(s) . The selected patients ,who booked for elective brain aneurysm repair/endovascular treatment with Flow diverter devices (FDS) called Pipeline embolization devices (PED), will qualify for registry participation . During the PED procedure, the study team will be using AneurysmFlow software to calculate a new metric called the MAFA ratio (Mean Aneurysm Flow Amplitude). By calculating the MAFA ratios intra-operatively, the interventionalist can adapt the therapeutic strategy in order to maximize the flow diverting effect on inducing complete aneurysm occlusions (thrombosis). Additionally, the purpose of this study is to further expand the body of clinical knowledge concerning the relationship between blood flow metrics as determined by the AneurysmFlow software and clinical outcome in patients undergoing treatment for intracranial aneurysms (IAs) with Pipeline and Pipeline Flex embolization devices. The study team aims to collect data at a 12 month follow-up period for each patient

Interventions

PROCEDURENeurovascular treatment of intracranial aneurysms

Endovascular treatment of intracranial aneurysms using flow diverting stents

DEVICEAneurysmFlow image processing software

Software to process and display images of intracranial aneurysm treatment using flow diverting stents.

Sponsors

Philips Healthcare
CollaboratorINDUSTRY
University Health Network, Toronto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

1. Subject with unruptured, large (≥8mm) saccular aneurysm(s) located in the anterior intracranial circulation and suitable for an endovascular treatment with a Flow Diverter Stent. 2. Subject has signed an institutionally approved research informed consent form. 3. Subject ≥ 18 years old.

Exclusion criteria

1. Subject with non-saccular brain aneurysm (s) such as:- dissecting; fusiform; atherosclerotic; mycotic; bifurcational. 2. Subject underwent a prior target brain aneurysm treatment with either endovascular (stenting, coiling) or surgical (clipping) techniques. 3. The endovascular treatment of subject's target aneurysm(s) was assisted with coils or intracranial stents (non-FDS) before the AneurysmFlow calculations. 4. Subject with partially thrombosed or recanalized target brain aneurysm(s). 5. Subject had prior significant or severe allergy to intra-arterial contrast medium uncontrolled by pre-procedure medications. 6. Subject with severe kidney disease (e-GFR \< 60). 7. Subject is not willing (or not able) to attend post FDS insertion follow up clinic visits requiring DSA, head MRI or CTA imaging.

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with complete aneurysm occlusion at 12 months based on contrast agent volume measurement in angiography.1 year≥86% complete aneurysm occlusion rate after 12 months post-treatment using optical flow analysis with a MAFA threshold ratio of 0.89, measured with an image processing tool.

Secondary

MeasureTime frameDescription
Number of participants with complete aneurysm occlusion at 6 months based on contrast agent volume measurement in angiography.6 months≥74% complete aneurysm occlusion rate after 6 months post-treatment using optical flow analysis with a MAFA threshold ratio of 0.89, measured with an image processing tool.
High sensitivity and specificity (> 80%) of the MAFA ratio to determine aneurysm occlusion rates based on ROC statistical calculations.1 yearData collected from the registry will be used to help determine a new, more optimal MAFA ratio threshold for predicting post-FDS aneurysm occlusion at 12 months post-treatment based on receiver operating characteristic (ROC) statistical curves.
Number of participants with treatment complications as assessed by an electronic patient record.1 yearPredictability of the MAFA ratio for treatment complications (aneurysm rupture, in-stent thrombosis, mass effect, using a correlation analysis.

Countries

Canada

Contacts

Primary ContactVitor Pereira, MD
vitor.pereira@uhn.ca416-603-5800
Backup ContactAlex Kostynskyy, MBBS
alex.kostynskyy@uhn.ca416-603-5800

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026